天弘国证生物医药ETF发起式联接C(011041)申购赎回 |
|
|
| 报告期 |
期初总份额(份) |
期末总份额(份) |
期间总申购份额(份) |
期间总赎回份额(份) |
期间净申赎份额(份) |
净申赎比例 |
| 2024/3/31 |
2,081,880,000 |
2,122,850,000 |
1,053,630,000 |
1,012,650,000 |
40,980,000 |
1.97% |
| 2023/12/31 |
1,492,040,000 |
2,081,880,000 |
4,588,320,000 |
3,998,480,000 |
589,840,000 |
39.53% |
| 2023/12/31 |
2,184,020,000 |
2,081,880,000 |
995,629,000 |
1,097,770,000 |
-102,141,000 |
-4.68% |
| 2023/9/30 |
2,222,850,000 |
2,184,020,000 |
1,170,100,000 |
1,208,930,000 |
-38,830,000 |
-1.75% |
| 2023/6/30 |
1,492,040,000 |
2,222,850,000 |
2,422,590,000 |
1,691,770,000 |
730,820,000 |
48.98% |
| 2023/6/30 |
1,635,180,000 |
2,222,850,000 |
1,457,190,000 |
869,516,000 |
587,674,000 |
35.94% |
| 2023/3/31 |
1,492,040,000 |
1,635,180,000 |
965,399,000 |
822,258,000 |
143,141,000 |
9.59% |
| 2022/12/31 |
1,109,920,000 |
1,492,040,000 |
3,697,290,000 |
3,315,170,000 |
382,120,000 |
34.43% |
| 2022/12/31 |
1,705,000,000 |
1,492,040,000 |
770,955,000 |
983,920,000 |
-212,965,000 |
-12.49% |
| 2022/9/30 |
1,234,520,000 |
1,705,000,000 |
1,377,770,000 |
907,286,000 |
470,484,000 |
38.11% |
| 2022/6/30 |
1,109,920,000 |
1,234,520,000 |
1,548,570,000 |
1,423,970,000 |
124,600,000 |
11.23% |
| 2022/6/30 |
1,056,790,000 |
1,234,520,000 |
860,132,000 |
682,401,000 |
177,731,000 |
16.82% |
| 2022/3/31 |
1,109,920,000 |
1,056,790,000 |
688,434,000 |
741,565,000 |
-53,131,000 |
-4.79% |
| 2021/12/31 |
292,374,000 |
1,109,920,000 |
3,069,790,000 |
2,252,240,000 |
817,550,000 |
279.62% |
| 2021/12/31 |
618,759,000 |
1,109,920,000 |
1,049,160,000 |
557,995,000 |
491,165,000 |
79.38% |
| 2021/9/30 |
474,690,000 |
618,759,000 |
908,580,000 |
764,512,000 |
144,068,000 |
30.35% |
| 2021/6/30 |
292,374,000 |
474,690,000 |
1,112,050,000 |
929,736,000 |
182,314,000 |
62.36% |
| 2021/6/30 |
373,694,000 |
474,690,000 |
880,431,000 |
779,435,000 |
100,996,000 |
27.03% |
| 2021/3/31 |
292,374,000 |
373,694,000 |
231,621,000 |
150,301,000 |
81,320,000 |
27.81% |
*注：新浪财经提醒：以上数据由合作伙伴提供，仅供参考，交易请以正式公告数据为准。
